MedTrace Logo

Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

NCT05817097 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 22119

Last updated 2023-07-20

No results posted yet for this study

Summary

The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction.

Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.

Conditions

  • Cerebral Infarction
  • Infarction, Brain
  • Dipeptidyl-Peptidase IV Inhibitors

Interventions

DRUG

Dipeptidyl peptidase-4 inhibitor

The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    collaborator INDUSTRY

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • DukYong Yoon, MD., PhD. · Department of Biomedical Systems Informatics,Yonsei University College of Medicine,Yongin,SouthKorea

  • Seong-Joon Lee, MD., PhD. · Department of Neurology, Ajou University School of Medicine, Suwon, South Korea

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-12-30
Completion
2024-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817097 on ClinicalTrials.gov